These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1566 related items for PubMed ID: 19135415

  • 1. Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial.
    Saito M, Aogi K, Sekine I, Yoshizawa H, Yanagita Y, Sakai H, Inoue K, Kitagawa C, Ogura T, Mitsuhashi S.
    Lancet Oncol; 2009 Feb; 10(2):115-24. PubMed ID: 19135415
    [Abstract] [Full Text] [Related]

  • 2. Palonosetron versus ondansetron for prevention of chemotherapy-induced nausea and vomiting in paediatric patients with cancer receiving moderately or highly emetogenic chemotherapy: a randomised, phase 3, double-blind, double-dummy, non-inferiority study.
    Kovács G, Wachtel AE, Basharova EV, Spinelli T, Nicolas P, Kabickova E.
    Lancet Oncol; 2016 Mar; 17(3):332-344. PubMed ID: 26795844
    [Abstract] [Full Text] [Related]

  • 3. Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron.
    Eisenberg P, Figueroa-Vadillo J, Zamora R, Charu V, Hajdenberg J, Cartmell A, Macciocchi A, Grunberg S, 99-04 Palonosetron Study Group.
    Cancer; 2003 Dec 01; 98(11):2473-82. PubMed ID: 14635083
    [Abstract] [Full Text] [Related]

  • 4. Transdermal granisetron versus palonosetron for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: a multicenter, randomized, open-label, cross-over, active-controlled, and phase IV study.
    Seol YM, Kim HJ, Choi YJ, Lee EM, Kim YS, Oh SY, Koh SJ, Baek JH, Lee WS, Joo YD, Lee HG, Yun EY, Chung JS.
    Support Care Cancer; 2016 Feb 01; 24(2):945-952. PubMed ID: 26265119
    [Abstract] [Full Text] [Related]

  • 5. Palonosetron: a unique 5-HT3 receptor antagonist indicated for the prevention of acute and delayed chemotherapy-induced nausea and vomiting.
    Rubenstein EB.
    Clin Adv Hematol Oncol; 2004 May 01; 2(5):284-9. PubMed ID: 16163194
    [Abstract] [Full Text] [Related]

  • 6. Efficacy of triplet regimen antiemetic therapy for chemotherapy-induced nausea and vomiting (CINV) in bone and soft tissue sarcoma patients receiving highly emetogenic chemotherapy, and an efficacy comparison of single-shot palonosetron and consecutive-day granisetron for CINV in a randomized, single-blinded crossover study.
    Kimura H, Yamamoto N, Shirai T, Nishida H, Hayashi K, Tanzawa Y, Takeuchi A, Igarashi K, Inatani H, Shimozaki S, Kato T, Aoki Y, Higuchi T, Tsuchiya H.
    Cancer Med; 2015 Mar 01; 4(3):333-41. PubMed ID: 25533447
    [Abstract] [Full Text] [Related]

  • 7. Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a network meta-analysis.
    Piechotta V, Adams A, Haque M, Scheckel B, Kreuzberger N, Monsef I, Jordan K, Kuhr K, Skoetz N.
    Cochrane Database Syst Rev; 2021 Nov 16; 11(11):CD012775. PubMed ID: 34784425
    [Abstract] [Full Text] [Related]

  • 8. Palonosetron: a second-generation 5-hydroxytryptamine receptor antagonist.
    Navari RM.
    Future Oncol; 2006 Oct 16; 2(5):591-602. PubMed ID: 17026451
    [Abstract] [Full Text] [Related]

  • 9. Infusion of palonosetron plus dexamethasone for the prevention of chemotherapy-induced nausea and vomiting.
    Hajdenberg J, Grote T, Yee L, Arevalo-Araujo R, Latimer LA.
    J Support Oncol; 2006 Oct 16; 4(9):467-71. PubMed ID: 17080735
    [Abstract] [Full Text] [Related]

  • 10. Combination therapy for chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy: palonosetron, dexamethasone, and aprepitant.
    Grote T, Hajdenberg J, Cartmell A, Ferguson S, Ginkel A, Charu V.
    J Support Oncol; 2006 Sep 16; 4(8):403-8. PubMed ID: 17004515
    [Abstract] [Full Text] [Related]

  • 11. Palonosetron plus 1-day dexamethasone for the prevention of nausea and vomiting due to moderately emetogenic chemotherapy: effect of established risk factors on treatment outcome in a phase III trial.
    Celio L, Denaro A, Agustoni F, Bajetta E.
    J Support Oncol; 2012 Sep 16; 10(2):65-71. PubMed ID: 22005217
    [Abstract] [Full Text] [Related]

  • 12. Palonosetron versus other 5-HT(3) receptor antagonists for prevention of chemotherapy-induced nausea and vomiting in patients with cancer on chemotherapy in a hospital outpatient setting.
    Balu S, Buchner D, Craver C, Gayle J.
    Clin Ther; 2011 Apr 16; 33(4):443-55. PubMed ID: 21635990
    [Abstract] [Full Text] [Related]

  • 13. A randomized phase III study evaluating the efficacy of single-dose NEPA, a fixed antiemetic combination of netupitant and palonosetron, versus an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC).
    Zhang L, Lu S, Feng J, Dechaphunkul A, Chang J, Wang D, Chessari S, Lanzarotti C, Jordan K, Aapro M.
    Ann Oncol; 2018 Feb 01; 29(2):452-458. PubMed ID: 29092012
    [Abstract] [Full Text] [Related]

  • 14. Comparison of an extended-release formulation of granisetron (APF530) versus palonosetron for the prevention of chemotherapy-induced nausea and vomiting associated with moderately or highly emetogenic chemotherapy: results of a prospective, randomized, double-blind, noninferiority phase 3 trial.
    Raftopoulos H, Cooper W, O'Boyle E, Gabrail N, Boccia R, Gralla RJ.
    Support Care Cancer; 2015 Mar 01; 23(3):723-32. PubMed ID: 25179689
    [Abstract] [Full Text] [Related]

  • 15. Palonosetron plus dexamethasone effectively prevents acute and delayed chemotherapy-induced nausea and vomiting following highly or moderately emetogenic chemotherapy in pre-treated patients who have failed to respond to a previous antiemetic treatment: comparison between elderly and non-elderly patient response.
    Massa E, Astara G, Madeddu C, Dessì M, Loi C, Lepori S, Mantovani G.
    Crit Rev Oncol Hematol; 2009 Apr 01; 70(1):83-91. PubMed ID: 18723369
    [Abstract] [Full Text] [Related]

  • 16. Efficacy and safety of casopitant mesylate, a neurokinin 1 (NK1)-receptor antagonist, in prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based highly emetogenic chemotherapy: a randomised, double-blind, placebo-controlled trial.
    Grunberg SM, Rolski J, Strausz J, Aziz Z, Lane S, Russo MW, Wissel P, Guckert M, Wright O, Herrstedt J.
    Lancet Oncol; 2009 Jun 01; 10(6):549-58. PubMed ID: 19428297
    [Abstract] [Full Text] [Related]

  • 17. Evaluation of clinical outcomes and efficacy of palonosetron and granisetron in combination with dexamethasone in Egyptian patients receiving highly emetogenic chemotherapy.
    A Mahrous M, A El-Azab G, A Tawfik H.
    Cancer Chemother Pharmacol; 2021 Jul 01; 88(1):121-129. PubMed ID: 33835230
    [Abstract] [Full Text] [Related]

  • 18. Efficacy of oral palonosetron compared to intravenous palonosetron for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy: a phase 3 trial.
    Boccia R, Grunberg S, Franco-Gonzales E, Rubenstein E, Voisin D.
    Support Care Cancer; 2013 May 01; 21(5):1453-60. PubMed ID: 23354552
    [Abstract] [Full Text] [Related]

  • 19. Palonosetron improves prevention of chemotherapy-induced nausea and vomiting in elderly patients.
    Aapro MS, Macciocchi A, Gridelli C.
    J Support Oncol; 2005 May 01; 3(5):369-74. PubMed ID: 16218261
    [Abstract] [Full Text] [Related]

  • 20. Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of moderately emetogenic chemotherapy or anthracycline and cyclophosphamide regimens in patients with cancer: a randomised, active-controlled, double-blind, phase 3 trial.
    Schwartzberg LS, Modiano MR, Rapoport BL, Chasen MR, Gridelli C, Urban L, Poma A, Arora S, Navari RM, Schnadig ID.
    Lancet Oncol; 2015 Sep 01; 16(9):1071-1078. PubMed ID: 26272768
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 79.